Type 2 diabetes: efficacy and safety of oral semaglutide

  • Avgerinos I & al.
  • Diabetes Obes Metab
  • 21 Oct 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with type 2 diabetes mellitus (T2DM), oral semaglutide can effectively and safely reduce blood glucose level, body weight, and systolic blood pressure (SBP).
  • However, it is associated with an increased risk for gastrointestinal adverse events.

Why this matters

  • Oral semaglutide, a novel once-daily glucagon-like peptide (GLP-1) receptor agonists developed as a tablet, has been recently approved for T2DM.
  • Individual randomised controlled trials (RCTs) have assessed its efficacy in reducing blood glucose and body weight, however, the totality of the evidence base has not been systematically reviewed

Study design

  • 11 randomised controlled trials (RCTs; n=9890) met eligibility criteria after a search across electronic databases.
  • Primary outcome: change in glycated haemoglobin (HbA1c) level from baseline.
  • Funding: None.

Key results

  • Oral semaglutide vs placebo was associated with reduction in:
    • HbA1c level (weighted mean difference [WMD], -0.89%; 95% CI -1.07 to -0.71; I2, 81%)
    • body weight (WMD, -2.99 kg; 95% CI -3.69 to -2.30; I2, 78%),
    • all-cause (OR, 0.58; 95% CI, 0.37-0.92) and cardiovascular (OR, 0.55; 95% CI, 0.31-0.98) mortality.
  • Semaglutide was also superior than other active comparators (including liraglutide, empagliflozin and sitaglipitin) in lowering HbA1c level (WMD, -0.35%; 95% CI, -0.43 to −0.26) and body weight (WMD, -1.48 kg; 95% CI, −2.28 to −0.67; I2, 82%).
  • Semaglutide showed reduction in SBP vs placebo (WMD, -3.16 mmHg; 95% CI, -4.56 to −1.77; I2, 52%) and other antidiabetic agents (WMD, -1.46 mmHg; 95% CI, -2.53 to -0.40).
  • Semaglutide did not increase the risk for myocardial infarction, stroke, severe hypoglycaemia, and diabetic retinopathy.
  • Incidence of nausea, vomiting, and diarrhoea increased with semaglutide vs placebo or other antidiabetic agents and events of acute pancreatitis were infrequent across all groups.

Limitations

  • High level of heterogeneity.